AbbVie bets $10 billion on ImmunoGen to boost its oncology portfolio
Shares of US antibody-drug conjugate (ADC) specialist ImmunoGen (Nasdaq: IMGN) shot up more that 83% to $29.46 pre-market today, on the news of a definitive agreement to be acquired by pharma major AbbVie (NYSE: ABBV).
The attraction for AbbVie is ImmunoGen’s flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class ADC approved for platinum-resistant ovarian cancer (PROC). The acquisition accelerates AbbVie's commercial and clinical presence in the solid tumor space. Additionally, ImmunoGen's follow-on pipeline of promising next-generation ADCs further complements AbbVie's ADC platform and existing programs.
The ADC market has attracted huge interest, for example Pfizer’s (NYSE: PFE) $43 billion acquisition of Seagen, as well as dozens of licensing deals. The sector was valued at $4 billion in 2021 and is forecast to rise to $13.13 billion by 2030, delivering a compund annual growth rate over 2021-2030 of 14.12%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze